# Dose Finding Study of RAD001 (Everolimus, Afinitor®) in Combination With BEZ235 in Patients With Advanced Solid Tumors

> **NCT01482156** · PHASE1 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 46 (actual)

## Conditions studied

- Advanced Solid Tumors
- Metastatic Breast Cancer
- Metastatic Renal Cell Carcinoma

## Interventions

- **DRUG:** RAD001 + BEZ235

## Key facts

- **NCT ID:** NCT01482156
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-01
- **Primary completion:** 2015-02
- **Final completion:** 2015-02
- **Target enrollment:** 46 (ACTUAL)
- **Last updated:** 2020-12-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01482156

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01482156, "Dose Finding Study of RAD001 (Everolimus, Afinitor®) in Combination With BEZ235 in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01482156. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*